Omada Health will present peer-reviewed research at the World Obesity and Weight Management Congress in Boston reporting that members of its GLP-1 Care Track lost more weight and improved body composition more than GLP-1 users receiving usual care. The findings were published in Diabetes, Obesity and Metabolism.

GLP-1 receptor agonists are the drug class that includes semaglutide and tirzepatide, prescribed for obesity and type 2 diabetes. The question Omada is trying to answer is not whether the drugs work, which is settled, but whether wrapping coaching and tracking around them changes what kind of weight comes off.

Key results

The study followed 245 adults who had started a GLP-1 within the previous eight weeks, 151 of them in Omada's program and 94 receiving usual care. After 12 weeks, the company reports that Omada members lost 6.0% of starting body weight compared with 3.3% for controls.

Body fat percentage fell 3.3% in the program group versus 1.6% in controls, and muscle mass percentage rose 0.6% versus 0.2%. Body composition was measured using at-home bioelectrical impedance scales.

What the program actually is

The GLP-1 Care Track bundles health coaches, peer support groups, digital meal and behavior tools, AI nutrition support and access to an exercise specialist. That is a lot of separate interventions in one package, and the study design does not isolate which of them did the work.

Omada also claims participants reported greater improvements in well-being, physical function and confidence for weight loss, plus larger reductions in depression and anxiety symptoms. Those are self-reported measures, and they come from the company rather than an independent evaluator.

Limitations

Twelve weeks is a short window for a drug class people stay on for years, and the muscle mass difference, 0.6% against 0.2%, is small enough that the scales used to measure it matter. The groups were not evenly sized, and the research was produced by the company whose product it evaluates.

Bottom line

The muscle preservation angle is the genuinely interesting part here, because lean mass loss is the open criticism of GLP-1 therapy that nobody has solved. Whether a 0.4 percentage point gap at 12 weeks means anything at 12 months is exactly what this study cannot tell you.